| Catalog Number |
03P81-25 |
| Medical Device Problem Code |
Incorrect, Inadequate or Imprecise Result or Readings (1535)
|
| Health Effect - Clinical Code |
No Information (3190)
|
| Date of Event |
03/11/2017
|
|
Type of Reportable Event
|
Malfunction
|
|
Additional Manufacturer Narrative
|
|
(b)(4).Apoc labeling was evaluated during the investigation as pertaining to the event.The investigation was completed on 04/05/2016.Retain product was tested and functioning according to specification.Investigation: the device history record (dhr) for this lot was reviewed.The lot passed finished goods (fg) release criteria.Forty retained cartridges from the lot were tested using a whole blood (wb) and a low hct blood sample.The compliant was not reproduced.Testing met the acceptance criteria found in q04.01.003 rev.X, appendix 1 - product complaint level 2 and level 3 investigation procedure.Three hundred returned cartridges from the lot were tested using wb and low hct blood samples and i-stat level 1 control (l1).The complaint was not reproduced.Testing met the acceptance criteria found in q04.01.003 rev.X, appendix 1 - product complaint level 2 and level 3 investigation procedure.No deficiency has been identified.Assessment: the complaint investigation concluded there was no product deficiency and that the i-stat cartridge lot is meeting specification.The samples were contrived for use in an internal apoc verification study.Patient results inside the ler zone pose a risk to patient safety.When values fall inside the ler zones, potential harm can occur to the patients if these results are utilized in medical decision-making.The ler established for the i-stat sodium assay is 18 mm up to 146 mm and 14 mm after that.
|
| |
|
Event or Problem Description
|
|
On (b)(6) 2015, abbott point of care was contacted by a customer regarding i-stat ec4+ cartridges that yielded suspected discrepant hct results.The issue occured internally during verification.There was no patient testing performed.(b)(6).At the time of the event there was no indication of a product malfunction based on the information provided and assessed by apoc, however this mdr is a retrospective filing in response to an observation from an fda inspection conducted may 8th to 12th, 2017 at abbott point of care ((b)(6)).
|
| |
|
Search Alerts/Recalls
|